AU5698394A - Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives - Google Patents

Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives

Info

Publication number: AU5698394A
Authority: AU; Australia
Prior art keywords: phenyloxyalkyl; new; calcium channel; cyclic amines; substituted cyclic
Prior art date: 1992-12-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU56983/94A

Other languages

English (en)

Inventor

Thomas Henry Brown

David Gywn Cooper

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Ltd

Original Assignee

SmithKline Beecham Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-15

Filing date

1993-12-07

Publication date

1994-07-04

1993-12-07 Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd

1994-07-04 Publication of AU5698394A publication Critical patent/AU5698394A/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Addiction (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AU56983/94A 1992-12-15 1993-12-07 Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives Abandoned AU5698394A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9226111		1992-12-15
GB929226111A GB9226111D0 (en)	1992-12-15	1992-12-15	Madicaments
PCT/EP1993/003473 WO1994013291A1 (en)	1992-12-15	1993-12-07	Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives

Publications (1)

Publication Number	Publication Date
AU5698394A true AU5698394A (en)	1994-07-04

Family

ID=10726633

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU56983/94A Abandoned AU5698394A (en)	1992-12-15	1993-12-07	Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives

Country Status (8)

Country	Link
EP (1)	EP0674514A1 (zh)
JP (1)	JPH08504419A (zh)
CN (1)	CN1091636A (zh)
AU (1)	AU5698394A (zh)
GB (1)	GB9226111D0 (zh)
MX (1)	MX9307946A (zh)
WO (1)	WO1994013291A1 (zh)
ZA (1)	ZA939317B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9314973D0 (en) *	1993-07-20	1993-09-01	Smithkline Beecham Plc	Medicaments
GB9411052D0 (en) *	1994-06-02	1994-07-20	Smithkline Beecham Plc	Medicaments
GB9411045D0 (en) *	1994-06-02	1994-07-20	Smithkline Beecham Plc	Compounds and use
AU2982595A (en) *	1994-07-14	1996-02-16	Smithkline Beecham Plc	Benzocycloalkylamine derivatives as calcium chanel antagonists
US5794887A (en)	1995-11-17	1998-08-18	Komerath; Narayanan M.	Stagnation point vortex controller
AU713236B2 (en) *	1996-02-15	1999-11-25	Sankyo Company Limited	Diarly alkane derivatives containing an alicyclic group, their preparation and their theraputic and prophylactic uses
US6110937A (en) *	1997-04-03	2000-08-29	Syntex Usa, Inc.	Phenoxymethyl piperidine derivatives for the treatment of neuropathic pain
CA2232147A1 (en) *	1997-04-03	1998-10-03	F. Hoffmann-La Roche Ag	Phenoxymethyl piperidine derivatives
AU1600599A (en)	1998-02-27	1999-09-15	Warner-Lambert Company	Heterocyclic substituted aniline calcium channel blockers
US6166052A (en)	1998-03-11	2000-12-26	Warner-Lambert Company	Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
EP1249245B1 (en) *	1999-12-21	2004-12-15	Mitsubishi Pharma Corporation	Remedies and/or preventives for nervous system disorders
US7294637B2 (en)	2000-09-11	2007-11-13	Sepracor, Inc.	Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
US7517892B2 (en)	2000-09-11	2009-04-14	Sepracor Inc.	Ligands for monoamine receptors and transporters, and methods of use thereof
CA2517081A1 (en)	2003-03-07	2004-09-16	Astellas Pharma Inc.	Nitrogen-containing heterocyclic derivatives having 2-6, disubtituted styryl
WO2005092885A1 (en)	2004-02-27	2005-10-06	Eli Lilly And Company	4-amino-piperidine derivatives as monoamine uptake inhibitors
US7417040B2 (en)	2004-03-01	2008-08-26	Bristol-Myers Squibb Company	Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
WO2007040682A1 (en) *	2005-09-21	2007-04-12	Decode Genetics Ehf.	Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation
WO2007073407A1 (en) *	2005-12-21	2007-06-28	Decode Genetics Ehf	Biaryl substituted nitrogen containing heterocycle inhibitors of lta4h for treating inflammation
US10772858B2 (en)	2015-05-01	2020-09-15	Georgia State University Research Foundation, Inc.	Benzhydrol derivatives for the management of conditions related to hypoxia inducible factors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1096441A (en) *	1964-01-15	1967-12-29	Bristol Myers Co	Ethers of benzyl phenols and a process for the preparation thereof
US3381013A (en) *	1964-01-15	1968-04-30	Bristol Myers Co	Heterocyclicamino ethers of benzylphenols
GB1203149A (en) *	1968-06-10	1970-08-26	Ici Ltd	Piperidine derivatives
GB1319252A (en) *	1969-06-05	1973-06-06	Ciba Geigy Ag	1-phenyl-alkanols and process for making same
DE2728898A1 (de) *	1977-06-27	1979-01-18	Thomae Gmbh Dr K	Neue morpholinderivate
DE2811952A1 (de) *	1978-03-18	1979-10-31	Merck Patent Gmbh	Phenoxyalkylamine und verfahren zu ihrer herstellung
FR2443246A1 (fr) *	1978-12-05	1980-07-04	Pharmindustrie	Nouveaux medicaments a base de derives de la phenyl-1 (piperidyl-4)-3 propanone-1
DK231088D0 (da) *	1988-04-28	1988-04-28	Ferrosan As	Piperidinforbindelser, deres fremstilling og anvendelse
IE66332B1 (en) *	1986-11-03	1995-12-27	Novo Nordisk As	Piperidine compounds and their preparation and use
US4822778A (en) *	1988-01-19	1989-04-18	Gunnar Aberg	Membrane stabilizing phenoxy-piperidine compounds and pharmaceutical compositions employing such compounds
US5169855A (en) *	1990-03-28	1992-12-08	Du Pont Merck Pharmaceutical Company	Piperidine ether derivatives as psychotropic drugs or plant fungicides
MX9100517A (es) *	1990-08-06	1992-04-01	Smith Kline French Lab	Compuestos
IE912759A1 (en) *	1990-08-06	1992-02-12	Smith Kline French Lab	Compounds
GB9113031D0 (en) *	1991-06-17	1991-08-07	Smithkline Beecham Plc	Compounds
WO1993015052A1 (en) *	1992-01-28	1993-08-05	Smithkline Beecham Plc	Compounds as calcium channel antagonists

1992
- 1992-12-15 GB GB929226111A patent/GB9226111D0/en active Pending
1993
- 1993-12-07 EP EP94902735A patent/EP0674514A1/en not_active Withdrawn
- 1993-12-07 AU AU56983/94A patent/AU5698394A/en not_active Abandoned
- 1993-12-07 JP JP6513782A patent/JPH08504419A/ja active Pending
- 1993-12-07 WO PCT/EP1993/003473 patent/WO1994013291A1/en not_active Application Discontinuation
- 1993-12-13 ZA ZA939317A patent/ZA939317B/xx unknown
- 1993-12-14 CN CN93112828A patent/CN1091636A/zh active Pending
- 1993-12-14 MX MX9307946A patent/MX9307946A/es unknown

Also Published As

Publication number	Publication date
CN1091636A (zh)	1994-09-07
MX9307946A (es)	1994-08-31
GB9226111D0 (en)	1993-02-10
EP0674514A1 (en)	1995-10-04
ZA939317B (en)	1995-06-13
WO1994013291A1 (en)	1994-06-23
JPH08504419A (ja)	1996-05-14

Publication	Publication Date	Title
AU5698394A (en)	1994-07-04	Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives
AU618870B2 (en)	1992-01-09	Cyclic amine compounds and their use
AU4825493A (en)	1994-04-26	Cyclohexyl amine derivatives and their use as tachykinin antagonists
AU5704894A (en)	1994-07-19	Phenyl derivatives useful as tachykinin antagonists
AU3930493A (en)	1993-11-18	Use of H-2 antagonists for treatment of gingivitis
HUP0000478A3 (en)	2000-10-30	Substituted cyclic amine as metalloprotease inhibitors and use of them for producing pharmaceutical compositions
FR2640503B1 (fr)	1994-10-21	Compositions de ciments dentaires d'ionomere-verre
AU4718093A (en)	1994-03-03	Substituted amines as tachykinin receptor antagonists
AU2002792A (en)	1992-12-21	Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
BR9204525A (pt)	1993-06-01	Composto ou mistura de compostos e composicao
AU3364693A (en)	1993-09-01	Azabricyclic compounds as calcium channel antagonists
AU3364493A (en)	1993-09-01	Compounds as calcium channel antagonists
NO943687D0 (no)	1994-10-03	4-(4'-piperidinyl eller 3'-pirrolidinyl) substituerte imidazoler som H3-reseptorantagonister og terapeutiske anvendelser derav
AU6721494A (en)	1994-12-12	Oral compositions containing triclosan for the treatment of aphthous ulcers
AU2071095A (en)	1995-10-17	Substituted cycloalkylamine derivatives and their use as calcium channel antagonists
AU2028892A (en)	1992-12-30	Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
AU2392392A (en)	1993-02-23	Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use
AU3220993A (en)	1993-06-28	Crystallizing enamel composition and method of making and using the same
GB9420114D0 (en)	1994-11-16	Substituted cyclic derivatives as novel antidegenerative agents
AU2759892A (en)	1993-05-21	N-aryl-n1-azabicyclo-ureas as 5-ht3 antagonists
NO924793D0 (no)	1992-12-11	Fremgangsmaate for fremstilling av kalsiumhydrosilikatbundne formlegemer
AU1583492A (en)	1992-09-15	Use of sigma receptor antagonists for treatment of amphetamine abuse
KR950700305A (ko)	1995-01-16	칼슘 통로 길항제로서 아자바이사이클로 화합물(Azabicyclo compounds as calcium channel antagonists)
AU7294094A (en)	1995-03-30	Substituted 6,11-ethano-6,11-dihydrobenzo(b) quinolizinium salts and compositions and methods of use thereof
TR27833A (tr)	1995-08-31	Antelmintik'lerin uygulanmasina mahsus ''pour-on'' formülasyonu.